Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials
Abstract
Background The DEPICT-1 and DEPICT-2 studies showed that dapagliflozin as an adjunct to insulin in individuals with inadequately controlled type 1 diabetes improved glycaemic control and bodyweight, without increase in risk of hypoglycaemia. We aimed to determine the effect of dapagliflozin on urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) using pooled data from the DEPICT studies. Methods In this post-hoc analysis, we used data pooled from both DEPICT studies (DEPICT-1 ran from Nov 11, 2014, to Aug 25, 2017; DEPICT-2 ran from July 8, 2015, to April 18, 2018), in which participants were aged 18-75 years, with inadequately controlled type 1 diabetes and with a baseline UACR of at least 30 mg/g. In the DEPICT studies, participants were randomly assigned (1:1:1) to receive dapagliflozin (5 mg or 10 mg) or placebo all plus insulin, for 24 weeks, with a 28-week long-term extension (ie, 52 weeks in total). In this post-hoc analysis, we assessed the percentage change from baseline in UACR and in eGFR, up to 52 weeks. UACR, eGFR, and safety were assessed in all eligible participants who had received at least one dose of study drug. HbA 1c , bodyweight, and systolic blood pressure were assessed in all participants who received at least one dose of study drug during the first 24-week period, and who had a baseline and any post-baseline assessment for that parameter. The DEPICT trials were registered with ClinicalTrials.gov, NCT02268214 (DEPIC…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In people with type 2 diabetes, improved cardiovascular outcomes (mainly due to reduction in congestive heart failure) and improved renal outcomes have been established, but there are only limited data on applicability to people with type 1 diabetes.
“In people with type 2 diabetes, improved cardiovascular outcomes, mainly due to a reduction in congestive heart failure, and improved renal outcomes have been established, but there are only limited data on the applicability of these findings to people with type 1 diabetes (262,263).”
Cites
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · see citing works
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · see citing works
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029190 · Cited by 813 · see citing works
Mathieu, C., Dandona, P., Gillard, P., Senior, P., Hasslacher, C., Araki, E., Lind, M., Bain, S. C., Jabbour, S., Arya, N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0623 · Cited by 252 · see citing works
Self-citationNordwall, M., Abrahamsson, M., Dhir, M., Fredrikson, M., Ludvigsson, J., & Arnqvist, H. J. (2015) · Diabetes Care · doi:10.2337/dc14-1203 · Cited by 161 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699 · see citing works
Kugathasan, L., Aronson, Y., Sridhar, V. S., Ni, H., Ouimet, J.-P., Limonte, C. P., Sarma, S., & Cherney, D. Z. I. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2537446 · Cited by 9 · see citing works
Bapat, P., Dhaliwal, S., Song, C., Zhang, Y., Scarr, D., Bakhsh, A., Budhram, D., Verhoeff, N. J., Weisman, A., Fralick, M., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0125 · Cited by 4 · see citing works
- Authors
- Groop, P.-H., Dandona, P., Phillip, M., Gillard, P., Edelman, S., Jendle, J., Xu, J., Scheerer, M. F., Thoren, F., Iqbal, N., Repetto, E., & Mathieu, C.
- Affiliations
- University of Helsinki (FI)
- University at Buffalo, State University of New York (US)
- Tel Aviv University (IL)
- Universitair Ziekenhuis Leuven (BE)
- University of California San Diego (US)
- Örebro University (SE)
- AstraZeneca (United States) (US)
- AstraZeneca (Germany) (DE)
- AstraZeneca (Sweden) (SE)
- Corresponding author
- Mathieu, Chantal
- ORCID
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 8
- Issue
- 10
- Pages
- 845-854
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W3086148163
- Cited by
- 79
- References
- 5
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 14 · 2023: 16 · 2022: 11 · 2021: 13 · 2020: 1
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novo Nordisk
- AstraZeneca
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- dapagliflozin, type 1 diabetes, insulin therapy, albuminuria, albumin-creatinine ratio, estimated glomerular filtration rate, renal function, SGLT2 inhibitors, inadequate glycaemic control, body weight, hypoglycemia, SGLT1 inhibition, SGLT2 inhibition
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Adolescent, Adult, Aged, Albuminuria, Benzhydryl Compounds, Blood Glucose, Creatinine, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Glomerular Filtration Rate, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Prognosis, Biomarkers, Diabetic Ketoacidosis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
